FPA-124

Cat. No.:	HY-15369
CAS No.:	902779-59-3
Molecular Formula:	$C_{11}H_9Cl_2CuN_3O_2S$
Molecular Weight:	381.73
Target:	Akt; Apoptosis
Pathway:	PI3K/Akt/mTOR; Apoptosis
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	FPA-124, a cell-permeable copper complex, is a selective Akt inhibitor with an IC_{50} of 0.1 μM. FPA-124 interacts with both the pleckstrin homology (PH) and the kinase domains of Akt. FPA-124 induces apoptosis[1][2].
In Vitro	FPA-124 exhibits dose-dependent growth inhibitory effects with IC_{50}s of 7, 10, 34, and 55 μM in BT20, PC-3, COLO 357 and BxPC-3 cancer cell lines, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	FPA-124 exhibits PKB (Akt protein) inhibitory activities and causes NF-κB inactivation in a well-established orthotopic pancreatic tumor model using COLO 357 cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Barve V, et al. Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells. J Med Chem. 2006 Jun 29;49(13):3800-8.

[2]. Biscetti F, et al. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc Diabetol. 2009 Sep 8;8:49.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA